Why the study?
The role of 18F-FDG PET/CT in assessing cardiotoxicity remains uncertain, and understanding how cardiovascular risk factors influence myocardial glucose uptake could enhance its application.
Is there an association between cardiac metabolic patterns on oncological PET/CT and cardiovascular risk factors in cancer patients?
Observational (n=983)
No
Is there an association between cardiac metabolic patterns on oncological PET/CT and cardiovascular risk factors in cancer patients?
Effect estimate: Male sex and higher weight independently predicted presence of myocardial FDG uptake (p=0.0008 and p=0.0001 respectively); diabetes and coronary artery disease independently predicted absence of uptake (p=0.01 and p=0.007 respectively)
Absolute Event Rate: 43.2% vs 56.8%
p-value: p=Male sex p=0.0008; weight p=0.0001; diabetes p=0.01; coronary artery disease p=0.007
Understanding how cardiovascular risk factors influence myocardial glucose uptake on PET/CT may improve its utility in evaluating cardiotoxicity in cancer patients.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ribeiro et al. (2026) conducted an observational in Adults with cancer undergoing oncologic 18F-fluorodeoxyglucose PET/CT scans, mean age 56 ± 15.8 years, 64% women, 39.9% hypertensive, 19.7% diabetic, 3% with coronary artery disease (n=983). Observation of myocardial FDG uptake on PET/CT scans vs. No myocardial FDG uptake was evaluated on Presence versus absence of visually defined myocardial 18F-FDG uptake on PET/CT scan (Male sex and higher weight independently predicted presence of myocardial FDG uptake (p=0.0008 and p=0.0001 respectively); diabetes and coronary artery disease independently predicted absence of uptake (p=0.01 and p=0.007 respectively), p=Male sex p=0.0008; weight p=0.0001; diabetes p=0.01; coronary artery disease p=0.007).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: